Viking Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for metabolic and endocrine disorders. The company's lead clinical program is VK2809, a tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRβ), which has demonstrated statistically significant reductions in liver fat and LDL-C in Phase IIb trials for biopsy-confirmed non-alcoholic steatohepatitis (NASH) and NAFLD. Viking is also highly watched for VK2735, a novel dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, currently undergoing Phase III clinical trials (VANQUISH-1 and VANQUISH-2) for obesity, alongside a promising oral formulation in Phase II development.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Simultaneous development of subcutaneous (injectable) and oral tablet formulations of VK2735, a dual GLP-1/GIP receptor agonist, to offer a flexible treatment paradigm (e.g., injectable induction followed by oral maintenance).
Expected impact: Aims to introduce the industry's first oral and subcutaneous dual GLP-1 and GIP co-agonist molecule for the treatment of obesity, offering exceptional efficacy, safety, and tolerability.
Advancing VK3019, a novel dual amylin and calcitonin receptor agonist (DACRA), to target metabolic pathways independent of GLP-1.
Expected impact: Provides a therapeutic option for patients who are non-responders or ineligible for GLP-1 therapies, expanding Viking's addressable metabolic market.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Secures commercial-scale manufacturing capacity, including active pharmaceutical ingredient (API) supply, fill/finish services, and capabilities to produce up to 100 million vials/syringes, 100 million auto-injectors, and 1 billion tablets annually.
Terms: Total of $150 million to be paid to CordenPharma over the period from 2026 to 2028.